The Effect and Safety of Pulsed Field Ablation (PFA) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Tongji Hospital144 enrolled

Overview

This study is aimed to evaluate the Efficacy and Safety of Pulsed Field Ablation (PFA) in Patients with Paroxysmal Atrial Fibrillation (PAF)

This clinical trial is a prospective, multi-center and single-arm Study. It will be carried out in 3 or more clinical trial institutions, and eligible patients with paroxysmal atrial fibrillation are enrolled. For those patients recruited, pulmonary vein isolation will be performed using pulsed field ablation device (Sichuan Jinjiang Electronic Technology Co., Ltd. Chengdu, China). The safety and efficacy of pulsed field ablation(PFA) in Patients with Paroxysmal Atrial Fibrillation (PAF) will be studied using ring-shaped pulsed field ablation catheter

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

144

Conditions

Paroxysmal Atrial Fibrillation

Interventions

Pulsed Field AblationDEVICE

pulmonary vein isolation will be performed with ring-shaped pulsed field ablation catheter directed by integrated three-dimensional mapping system

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: Paroxysmal Atrial Fibrillation (PAF) Exclusion Criteria: 1. A history of atrial fibrillation ablation; 2. Left ventricular ejectfraction(LVEF)\<35% 3. Left Atrium(LA)（echocardiography）\>55mm 4. Thrombus in the left atrial or heart before surgery 5. New York Heart Association(NYHA) grade Ⅲ-Ⅳ 6. second or third degree atrioventricular block 7. Significant congenital heart defects (e.g. atrial septal defect or severe pulmonary vein stenosis, but except foramen ovale) 8. Prosthetic valves 9. Pacemakers or defibrillators (ICD) 10. Hypertrophic cardiomyopathy, chronic obstructive pulmonary disease or myxoma 11. Symptomatic carotid stenosis 12. Untreated or uncontrolled hyperthyroidism or hypothyroidism 13. Systemic active infection 14. Renal failure with obvious bleeding tendency or undergoing hemodialysis 15. Myocardial infarction or any cardiac intervention/open surgery within 3 months 16. Stroke or transient ischemic attack within 6 months 17. Obvious contraindication for interventional surgery who were determined by the investigator to be unable to undergo ablation 18. Pregnant or lactating women or those who planned to have a family during the study period 19. Have participated in clinical trials of other drugs or medical devices within 3 months 20. Unsuitable to participate in this clinical trial by the investigator

Locations (1)

Tongji Hospital

Wuhan, Hubei, China

RECRUITING

Outcomes

Primary Outcomes

Immediate success rate

Procedural success for PAF is defined as the achievement of complete pulmonary venous electrical isolation

Time frame: during procedure

Secondary Outcomes

Procedural success rate at 12 months after procedure

Procedural success for PAF was defined as the absence of atrial fibrillation/atrial flutter/atrial tachycardia (duration ≥30s) without antiarrhythmic drugs between 3 months and 12 months after ablation

Time frame: between 3 months and 12 months after ablation

The occurrence of hospitalizations or emergency department visit due to symptoms of atrial arrhythmia at 6-month and 12-month follow-up

The occurrence of hospitalizations or emergency department visit due to symptoms of atrial arrhythmia at 6-month and 12-month of follow-up

Time frame: at 6-month and 12-month

Evaluation of pulsed electric field ablation instrument

operational stability; Hardware Connection validity; Software operability; degree of satisfaction

Time frame: baseline

Evaluation of a disposable cardiac pulsed electric field ablation catheter

Whether the catheter can reach its desired location smoothly; X ray and shadow;development is clear; Whether the conduit bend is adjustable; Whether the electrophysiological signal is clear and stable; When used together with the mapping system, whether mapping and 3D modeling can be carried out; When used in conjunction with the mapping system, can the catheter be located; Is it possible to stimulate normally; Whether the ablation can be performed normally; Were there any blood clots after withdrawal; Is the tube body intact after withdrawal from the body; Surgeon satisfaction

Time frame: baseline

Central Contacts

Daowen Wang, PhD

CONTACT

86-72-83662842 dwwang@tjh.tjmu.edu.cn

Yan Wang, PhD

CONTACT

86-72-83663280 newswangyan@tjh.tjmu.edu.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.